Latest Regulatory News

Equatorial Resources reports a postponed arbitration hearing over Congo iron ore disputes and seeks clarity on Guinea permit cancellations, while maintaining a solid cash reserve.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Lindian Resources secures official government confirmation that its Kangankunde Rare Earths Project is exempt from Malawi’s new raw mineral export ban, ensuring uninterrupted progress toward production.

Fitzroy River Corporation reported steady royalty income for the June quarter and highlighted significant progress on several royalty projects, including government approvals for Buru Energy’s Rafael Gas Project and a major equity raise for Endura Mining’s Snowy River Gold development.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Nagambie Resources has restarted diamond drilling at its Nagambie Mine, targeting new high-grade antimony-gold lodes east of its current resource, supported by a $1.2 million capital raise and strategic board appointment.

Ainsworth Game Technology’s board unanimously backs Novomatic’s $1.00 per share takeover offer, while a competing proportional bid at $1.30 per share emerges from a key shareholder.

Helia Group’s 3Q25 APRA data reveals rising gross written premiums despite government scheme pressures, while a Board review confirms strategic focus on the Australian LMI market with significant cost cuts.

LGI Limited has launched a $5 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy additional shares at a slight discount. The capital raise aims to fund the acceleration of key renewable energy projects.